Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Jan 17;15(3):488.
doi: 10.3390/nu15030488.

Ongoing Treatment with a Spore-Based Probiotic Containing Five Strains of Bacillus Improves Outcomes of Mild COVID-19

Adrian Catinean  1 , Anamaria Sida  1 , Celina Silvestru  1 , Gheorghe G Balan  2
Affiliations
Observational Study

Ongoing Treatment with a Spore-Based Probiotic Containing Five Strains of Bacillus Improves Outcomes of Mild COVID-19

Adrian Catinean et al. Nutrients. .

Abstract

Spore-based Bacillus probiotic treatment improves intestinal health. The intestinal microbiota influences both the innate and adaptive immune responses. As such, the influence of ongoing spore-based probiotic treatment (five probiotic strains of Bacillus) on the clinical outcomes of mild COVID-19 was evaluated in this retrospective, observational study. Demographics, medical history, probiotic use, and COVID-19 symptom information were collected. The study included 120 patients with a PCR-confirmed SARS-CoV-2 infection and mild COVID-19 symptoms. The probiotic group (n = 60) comprised patients with ongoing probiotic treatment (≥1 month); the control group comprised patients not taking probiotics (n = 60). The primary outcome was time to symptom resolution; secondary outcomes included time to fever resolution and presence of digestive symptoms. The probiotic group had a significantly shorter time to symptom resolution (mean (95% confidence interval) days: control group, 8.48 (6.56, 10.05); probiotic group, 6.63 (5.56; 6.63); p = 0.003) and resolution of fever (control group, 2.67 (1.58, 3.61); probiotic group, 1.48 (1.21, 2.03); p < 0.001). More patients in the probiotic group (n = 53) than in the control group (n = 34) did not have digestive symptoms (p < 0.001). Among adults with mild COVID-19, participants receiving ongoing probiotic treatment had a shorter clinical course, and fewer had digestive symptoms compared with those not taking probiotics.

Keywords: Bacillus; COVID-19; SARS-CoV-2; fever in COVID-19 infection; gastrointestinal COVID-19 symptoms; gut microbiota; gut–lung axis; immunomodulation; probiotics; time to symptom resolution.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to disclose.

Figures

Figure 1
Figure 1
Participant disposition.
Figure 2
Figure 2
Time to resolution of all COVID-19 symptoms. The orange line represents participants in the probiotic group, and the blue line represents participants in the control group. CI, confidence interval; HR, hazard ratio.
Figure 3
Figure 3
Kaplan–Meier curve showing time to resolution of fever. The orange line represents participants in the probiotic group, and the blue line represents participants in the control group. CI, confidence interval; HR, hazard ratio.
Figure 4
Figure 4
Distribution of maximum fever for individual participants. The orange bars represent participants in the probiotic group, and the blue bars represent participants in the control group. IQR, interquartile range; SD, standard deviation.
See this image and copyright information in PMC

References

    1. Zuo T., Zhang F., Lui G.C.Y., Yeoh Y.K., Li A.Y.L., Zhan H., Wan Y., Chung A.C.K., Cheung C.P., Chen N., et al. Alterations in Gut Microbiota of Patients with COVID-19 during Time of Hospitalization. Gastroenterology. 2020;159:944–955. doi: 10.1053/j.gastro.2020.05.048. - DOI - PMC - PubMed
    1. WHO Coronavirus (COVID-19) Dashboard. [(accessed on 16 January 2023)]. Available online: https://covid19.who.int/#:~:text=Globally%2C%20as%20of%204%3A54pm,vaccin....
    1. Clemente J.C., Manasson J., Scher J.U. The role of the gut microbiome in systemic inflammatory disease. BMJ. 2018;360:j5145. doi: 10.1136/bmj.j5145. - DOI - PMC - PubMed
    1. Miyauchi E., Shimokawa C., Steimle A., Desai M.S., Ohno H. The impact of the gut microbiome on extra-intestinal autoimmune diseases. Nat. Rev. Immunol. 2023;23:9–23. doi: 10.1038/s41577-022-00727-y. - DOI - PubMed
    1. Wu H.J., Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes. 2012;3:4–14. doi: 10.4161/gmic.19320. - DOI - PMC - PubMed

Publication types